カテゴリ： GlobalData, アメリカ, 企業調査

Onconova Therapeutics Inc (ONTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Onconova Therapeutics Inc (ONTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9796
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：77
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib, briciclib and recilisib. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partners with biopharmaceutical companies and medical organizations in the US. The company operates through its offices in Newtown and Pennington, the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

Onconova Therapeutics Inc (ONTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Onconova Therapeutics Raises US$50 Million In Venture Financing 11
Onconova Therapeutics Raises US$26.4 Million In Venture Financing Round 12
Partnerships 13
Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 13
Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 14
Onconova Therapeutics Enters into Research Partnership with SymBio Pharma 15
GVK Biosciences Enters Into Agreement With Onconova Therapeutics To Develop New Cancer Drugs 16
Licensing Agreements 17
Pint Pharma Enters into Licensing Agreement with Onconova Therapeutics 17
HanX Biopharma Enters into Licensing Agreement with Onconova Therapeutics 18
Baxter International Enters into Licensing Agreement with Onconova Therapeutics 19
Equity Offering 20
Onconova Therapeutics Raises USD28.7 Million Public Offering of Shares and Warrants 20
Onconova Therapeutics Raises USD1.3 Million in Private Placement of Shares 22
Onconova Therapeutics Raises USD10 Million in Public Offering of Shares 23
Onconova Therapeutics Raises USD1.4 Million in Private Placement of Shares 25
Onconova Therapeutics Plans to Raise up to USD84.5 Million in Public Offering of Shares 26
Onconova Therapeutics Raises USD5.2 Million in Public Offering of Shares 27
Onconova Therapeutics Raises USD17.5 Million in Rights Offering of Units 28
Onconova Therapeutics Raises USD1.8 Million in Private Placement of Shares 30
Onconova Therapeutics Raises USD1.5 Million in Private Placement of Shares 31
Onconova Therapeutics Completes IPO Of Shares For US$89 Million 32
Onconova Therapeutics Inc – Key Competitors 34
Onconova Therapeutics Inc – Key Employees 35
Onconova Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 14, 2018: Onconova Therapeutics reports business highlights and financial results for second quarter 2018 37
May 15, 2018: Onconova Therapeutics Reports Business Highlights and Financial Results for First Quarter 2018 39
Mar 08, 2018: Onconova Therapeutics Reports Business Highlights and Full Year 2017 Financial Results 40
Nov 09, 2017: Onconova Therapeutics Reports Third Quarter 2017 Financial Results 42
Aug 15, 2017: Onconova Therapeutics Reports Recent Business Highlights and Second Quarter 2017 Financial Results 43
May 15, 2017: Onconova Therapeutics Reports Recent Business Highlights and First Quarter 2017 Financial Results 45
Mar 27, 2017: Onconova Therapeutics Reports Recent Business Highlights and Year-end 2016 Financial Results 47
Corporate Communications 48
Nov 07, 2018: Onconova welcomes Richard Woodman, M.D., as Chief Medical Officer 48
Jun 21, 2018: Onconova Therapeutics Promotes Steven M. Fruchtman To President 49
Product News 50
11/15/2017: Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia 50
07/25/2017: Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies” 52
02/20/2018: Onconova Announces Presentation on its Acute Myeloid Leukemia Drug Candidate ON-150030 at 2018 American Chemical Society National Meeting and Expo 53
02/02/2018: Onconova Announces Presentation Of Mechanism Of Action Studies Of Rigosertib Combination With Azacitidine At American Association For Cancer Epigenetics Research Conference 54
Clinical Trials 55
Jan 17, 2018: Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis 55
Dec 12, 2017: Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Meeting 57
Nov 16, 2017: Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting 59
Nov 09, 2017: Onconova Therapeutics Provides Update on Rigosertib 61
Nov 01, 2017: Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting 64
Oct 10, 2017: Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 65
Oct 04, 2017: Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City 66
Jun 30, 2017: SymBio Pharmaceuticals Announces Initiation in Japan of the Phase I Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 67
Jun 26, 2017: Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid 68
Jun 05, 2017: Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting 70
May 22, 2017: Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association 72
May 18, 2017: Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting 74
May 01, 2017: Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes 75
Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onconova Therapeutics Raises US$50 Million In Venture Financing 11
Onconova Therapeutics Raises US$26.4 Million In Venture Financing Round 12
Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 13
Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 14
Onconova Therapeutics Enters into Research Partnership with SymBio Pharma 15
GVK Biosciences Enters Into Agreement With Onconova Therapeutics To Develop New Cancer Drugs 16
Pint Pharma Enters into Licensing Agreement with Onconova Therapeutics 17
HanX Biopharma Enters into Licensing Agreement with Onconova Therapeutics 18
Baxter International Enters into Licensing Agreement with Onconova Therapeutics 19
Onconova Therapeutics Raises USD28.7 Million Public Offering of Shares and Warrants 20
Onconova Therapeutics Raises USD1.3 Million in Private Placement of Shares 22
Onconova Therapeutics Raises USD10 Million in Public Offering of Shares 23
Onconova Therapeutics Raises USD1.4 Million in Private Placement of Shares 25
Onconova Therapeutics Plans to Raise up to USD84.5 Million in Public Offering of Shares 26
Onconova Therapeutics Raises USD5.2 Million in Public Offering of Shares 27
Onconova Therapeutics Raises USD17.5 Million in Rights Offering of Units 28
Onconova Therapeutics Raises USD1.8 Million in Private Placement of Shares 30
Onconova Therapeutics Raises USD1.5 Million in Private Placement of Shares 31
Onconova Therapeutics Completes IPO Of Shares For US$89 Million 32
Onconova Therapeutics Inc, Key Competitors 34
Onconova Therapeutics Inc, Key Employees 35
Onconova Therapeutics Inc, Subsidiaries 36

List of Figures
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Onconova Therapeutics Inc (ONTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • OraSure Technologies Inc (OSUR)-医療機器分野：企業M&A・提携分析
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; and ant …
  • NXP Semiconductors NV (NXPI)：企業の財務・戦略的SWOT分析
    NXP Semiconductors NV (NXPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • MonTa Biosciences ApS：製薬・医療：M&Aディール及び事業提携情報
    Summary MonTa Biosciences ApS (MonTa Biosciences) is a biotechnology company that develops and commercializes immuno-oncology therapeutics for cancer therapy. Its pipeline products include MBS2, and MBS5 used for the treatment of cancer and infectious diseases. The company’s technology is based on T …
  • Genome Institute of Singapore：医療機器：M&Aディール及び事業提携情報
    Summary Genome Institute of Singapore (GIS) is a research institute that provides research programs and services in different areas. The institute concentrates on genomic sciences to improve public health and prosperity in Singapore. It operates technology and comprises early career researchers such …
  • Biolase Inc (BIOL)：医療機器：M&Aディール及び事業提携情報
    Summary Biolase Inc (Biolase) develops, manufactures, markets and sells dental lasers and related products. It also distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. The company offers two categories of laser systems: WaterLase systems and Diod …
  • Assurant, Inc.：企業の戦略・SWOT・財務情報
    Assurant, Inc. - Strategy, SWOT and Corporate Finance Report Summary Assurant, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Revolution Lighting Technologies Inc (RVLT)：企業の財務・戦略的SWOT分析
    Revolution Lighting Technologies Inc (RVLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Walmart Chile S.A.：企業の戦略的SWOT分析
    Walmart Chile S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • The Quaker Oats Company：企業の戦略・SWOT・財務情報
    The Quaker Oats Company - Strategy, SWOT and Corporate Finance Report Summary The Quaker Oats Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sumatec Resources Bhd (SUMATEC)：石油・ガス：M&Aディール及び事業提携情報
    Summary Sumatec Resources Bhd (Sumatec) is an oilfield service provider that offers of construction and drilling services to the oil and gas industry. The company’s services include engineering and construction for oil and gas facilities, oil and gas assets development, supply and management of onsh …
  • Foster Electric Co Ltd：企業の戦略・SWOT・財務情報
    Foster Electric Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Foster Electric Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Globus Medical, Inc. (GMED)-医療機器分野：企業M&A・提携分析
    Summary Globus Medical, Inc. (Globus) is a medical device company which manufactures and markets musculoskeletal implants with focus on the treatment of spine disorders. The company’s product portfolio includes biomaterial products, cervical, deformity, intervertebral fusion, minimally invasive, mot …
  • Nichi-Iko Pharmaceutical Co Ltd (4541)：企業の財務・戦略的SWOT分析
    Summary Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahis …
  • Ontario Municipal Employees Retirement System：電力：M&Aディール及び事業提携情報
    Summary Ontario Municipal Employees Retirement System (OMERS) offers pension benefits to government employees, beneficiaries, and retirees from diverse sectors such as municipalities, libraries, police and fire departments, schools, and other agencies in Ontario. It is sponsored by OMERS Sponsors Co …
  • Teva Pharmaceutical Industries Ltd (TEVA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, …
  • Foster Farms：企業の戦略・SWOT・財務情報
    Foster Farms - Strategy, SWOT and Corporate Finance Report Summary Foster Farms - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bulova Technologies Group, Inc.：戦略・SWOT・企業財務分析
    Bulova Technologies Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bulova Technologies Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cap Gemini S.A.：戦略・SWOT・企業財務分析
    Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report Summary Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Chennai Petroleum Corporation Ltd (CHENNPETRO)：企業の財務・戦略的SWOT分析
    Chennai Petroleum Corporation Ltd (CHENNPETRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Eby-Brown Company LLC：企業の戦略・SWOT・財務情報
    Eby-Brown Company LLC - Strategy, SWOT and Corporate Finance Report Summary Eby-Brown Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆